Drugs / ZB716
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04669587 | Jul 2021 → Jan 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | EnhancedBio USA Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZB716 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669587 ↗ |
| Known as | Fulvestrant-3-boronic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL4526356 ↗ |
| Action | Inhibit | “selective ERα degrader with full ER antagonism” NCT04669587 ↗ |
| Modality | Small molecule | — CHEMBL4526356 ↗ |
| Route | Oral | “Pharmaceutical form: capsule Route of administration: oral” NCT04669587 ↗ |